All In Biotech

Drug Trial Radar · NCT07653100

A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF

A PHASE 3 STUDY IN INDIA TO DESCRIBE THE SAFETY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN ADULTS

Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 540 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

540

Planned (sponsor's estimate)

Start

Jun 22, 2026

Primary completion

Jan 25, 2027

Study completion Jan 25, 2027

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jun 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this phase 3 multicenter, double-blinded, placebo-controlled study in India is to learn about the safety and immunogenicity of RSVpreF in adults.

Conditions

  • Respiratory Syncytial Virus (RSV)

Interventions

  • RSVpreFBiological

    RSVpreF Vaccine

  • PlaceboBiological

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants reporting local reactions within 7 days following investigational product administrationTime frame: Within 7 days
  2. Percentage of participants reporting systemic events within 7 days following investigational product administrationTime frame: Within 7 days
  3. Percentage of participants reporting adverse events (AEs) through 1 month following investigational product administrationTime frame: 1 month after vaccination
  4. Percentage of participants reporting serious adverse events (SAEs) throughout the studyTime frame: 3 months after vaccination
  5. Neutralizing Titers (NTs) for RSV A and RSV B expressed as Geometric Mean Titers (GMT)Time frame: Before vaccination, 1 month after vaccination
  6. NTs for RSV A and RSV B expressed as Geometric Mean Fold Rise (GMFR)Time frame: Before vaccination, 1 month after vaccination
  7. NTs for RSV A and RSV B expressed as seroresponse rateTime frame: 1 month after vaccination

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • King George Hospital

    Visakhapatnam, Andhra Pradesh, India · Recruiting

  • BGS Global Institute of Medical Sciences (BGSGIMS)

    Bangalore, Karnataka, India · Recruiting

  • Radhakrishna Multispeciality Hospital and IVF Center

    Bangalore, Karnataka, India · Recruiting

  • Belagavi Institute of Medical Sciences - Belagavi

    Belagavi, Karnataka, India · Recruiting

  • Suyog Hospital

    Nashik, Maharashtra, India · Recruiting

  • Bharati Vidyapeeth {Deemed to be University) Medical College Hospital & Research Centre

    Pune, Maharashtra, India · Recruiting

  • Aakash Healthcare Private Limited

    Dwarka, National Capital Territory of Delhi, India · Recruiting

  • All India Institute Of Medical Sciences

    New Delhi, National Capital Territory of Delhi, India · Recruiting

  • Sir Ganga Ram Hospital

    New Delhi, National Capital Territory of Delhi, India · Recruiting

  • Maharaja Agrasen Superspeciality Hospital

    Jaipur, Rajasthan, India · Recruiting

  • SRM Medical College Hospital and Research Centre - Kattankulathur

    Chengalpattu, Tamil Nadu, India · Recruiting

  • Chettinad Hospital and Research Institute

    Kelambākkam, Tamil Nadu, India · Recruiting

  • Institute of Post Graduate Medical Education & Research, SSKM Hospital

    Kolkata, West Bengal, India · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.